Abstract-This document reports the performance of anti-PSMA monoclonal antibodies in microfludic devices for the isolation of circulating prostate cancer cells.
I. INTRODUCTION
Monoclonal antibody J591, an antibody that is highly specific for prostate-specific membrane antigen (PSMA) [1] , is here applied to microfluidic devices for the capture of LNCaPs, a PSMA-expressing immortalized prostate cancer cell line. Here we report the capture efficiency of monoclonal anti-PSMA antibodies for cell isolation over a range of concentrations and shear stresses.
Microfluidic Capture of Prostate Circulating Tumor Cells
Patients suffering from metastatic prostate cancer often shed tumor cells, called prostate circulating tumor cells (PCTCs), into the bloodstream [2, 3] . While these PCTCs are rare, as few as one cell per 10 9 hematologic cells in blood, it is believed that they contribute to metastatic progression [4] . Thus PCTC enumeration is used clinically as a prognostic indicator of patient survival [5] . The capture and release of PCTCs may enable early clinical assessment of metastatic process and chemotherapeutic response, as well as genetic and pharmacological evaluation of cancer cells.
Existing commercial and research devices for the immunocapture of rare cancer cells use EpCAM antibodies, which capture many circulating epithelial cells and large numbers of leukocytes [6] . Consequently, captured cell purity is widely variable and often below 50%. We have previously reported high-efficiency and high-purity capture of PCTCs from castrate-resistant prostate cancer patient blood samples with monoclonal antibody J591, an antibody that is highly specific for PSMA [7] . Here we report the capture efficiency of monoclonal anti-PSMA antibodies for cell isolation.
II. EXPERIMENTAL PLATFORM

A. Experimental Microfluidic Platform
Hele-Shaw flow cells provide a simple and useful platform through which to optimize flow characteristics for the capture of rare cells. Cell capture within the microfluidic device depends on the number of potential interactions a cell will have with immunocoated surfaces as well as the contributions of shear stress [7, 8] . Preferable flow parameters constitute flow conditions that balance cell viability with high capture efficiency and purity. A Hele-Shaw flow cell facilitates analysis of known flow characteristics, specifically shear stress, because the fluid velocity field variations in the plane of the device are often amenable to analytical solution. The currently implemented Hele-Shaw cell is shown in Fig. 1 [9] . This device is based on the analytical solution for potential stagnation flow, and maintains the linear decrease in shear stress predicted by the analytical solution along approximately 50% of its length (the experimentally implemented inlets and outlets create edge effects because they deviate from those matching the analytical solution). Using flow through this Hele-Shaw cell, each experimental run characterizes cell adhesion over a wide range of shear stresses, corresponding to those experienced within microfluidic immunocapture devices.
B. Microdevice Functionalization
Hele-Shaw flow cells were functionalized with an amineterminated surface via a multi-step process using 4% (v/v) MPTMS (3-mercaptopropyl trimethoxysilane) [SigmaAldrich, St. Louis, MO] in ethanol solution for 30 minutes followed by an incubation with a 1 mM GMBS (N-gmaleimidobutyryloxy succinimide ester) [Pierce Biotechnology, Rockford, IL] in ethanol solution for 20 minutes. Next, a layer of NeutrAvidin [Pierce Biotechnology, Rockford, IL] was covalently attached to the surface by incubating for 60 minutes with a 25 ng/mL in phosphate-buffered saline (PBS) solution. Lastly, we immobilized biotinylated monoclonal antibodies, J591 and J415, both of which have a high binding avidity to and specificity for epitopes on the extracellular prostate specific membrane antigen (PSMA) domain, for prostate circulating tumor cell capture, at various antibody concentrations [1] . 
III. CAPTURE EXPERIMENTS
A. Cell Preparation
All capture experiments were conducted with LNCaP cells, an immortalized prostate cancer cell line that expresses PSMA. LNCaP cells were cultured in T75 culture flasks at 37 degrees Celsius in a 5% carbon dioxide humidified environment. Cells were incubated in RPMI-1640 fortified with 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic (AB-AM). To prepare cells for experiments, they were removed from the culture flasks and centrifuged at 150g for 5 minutes and resuspended in 1mM ethylenediaminetetraacetic acid (EDTA) in 1% (m/v) bovine serum albumin (BSA) in phosphate buffer solution (PBS) for 3e10 5 LNCaP cells/mL.
B. Experimental Protocol
These cells were flowed through the Hele-Shaw microdevices at a rate of 0.2 mL/hr using a Fusion 100 (Chemyx Inc.) syringe pump. A wash flow of 1% BSA in PBS with 1% Trypan blue was flowed through the chamber at 0.2 mL/hr for 15 minutes. Cell adhesion was quantified using a Nikon Eclipse TE2000U inverted microscope (Nikon, Japan) and a data collection tool to image predetermined regions; for each unique shear stress region, one adhesion count was conducted, only including live cells as indicated by trypan blue exclusion. Images were taken at a 20x magnification under bright field with a camera that was connected to the Nikon microscope. For the capture experiments, cell count values were collected for 14 unique shear stress regions with at least 8 repetitions.
IV. RESULTS
The results of capture experiments using immunocoated Hele-Shaw flow cells is shown in Fig. 2 . The data indicate the relative performance of biotinylated-J591, biotinylated-J415, and a 50/50 hybrid of biotinylated-J591 with biotinylated-J415; in all cases, antibody solutions with a total concentration of 10µg of antibody per milliliter of 1% (w/v) BSA in PBS were used when functionalizing the surface. As expected, the capture of LNCaP cells decreased as a function of increasing shear stress. J591 and J415 are anti-PSMA monoclonal antibodies that bind to external epitopes on the PSMA protein; J415 and J591 do not compete with each other for binding [1, 10] . Because of this non-competitive nature, it was expected that hybridizing the surface chemistry would produce a synergistic effect that would enhance cell capture. Because of this non-competitive nature, it was expected that hybridizing the surface chemistry would produce a synergistic effect that would enhance cell capture. As can be seen in Fig. 2 , the performance of the antibody hybrid closely matches that of the J415 surface, yielding a decreased ability to capture as compared to J591. The mechanism for this performance is currently unknown. We also find that the concentration of antibody in the incubating solution (and thus the immobilized antibody on the surface following functionalization) impacts cell capture. Cell capture increases with increasing antibody concentration, as seen in Fig. 3 . Thus capture characteristics of various immunocoated surfaces inform design for microfluidic devices for the isolation of circulating tumor cells from patient blood samples. 
